Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels

Clinical Proteomics

Jennifer E Hardingham⁴  Adrian G Cummins³  Gemma Hardi⁴  Zaipul Izwan⁴  Timothy J Price¹  Tim Chataway²  Georgia Arentz⁴ 

[1] Department of Medicine, University of Adelaide, SA 5005, Australia;Department of Physiology, Flinders University, Bedford Park, SA 5042, Australia;Department of Gastroenterology and Hepatology, The Queen Elizabeth Hospital, Woodville, SA 5001, Australia;Department of Physiology, University of Adelaide, SA 5005, Australia

关键词: angiogenesis;    pericyte;    biomarker;    desmin;    2D DIGE;    Colorectal cancer;   

Others  :  1026364
DOI  :  10.1186/1559-0275-8-16

 received in 2011-11-21, accepted in 2011-12-05,  发布年份 2011

【 摘 要 】

Introduction

Biomarkers that improve stratification of colorectal cancer patients for adjuvant therapy versus resection alone, or that are predictive of response to therapeutic agents, have the potential to greatly improve patient selection for such therapies. The aim was to determine proteins differentially expressed within the malignant epithelial glands and closely associated stromal elements compared to matched normal mucosa, and to characterise the over-expression of one such protein as a potential biomarker.

Methods

Protein from laser microdissected tumor and normal mucosa was analysed by two dimensional difference gel electrophoresis (2D DIGE) and mass spectrometry to determine differentially over expressed tumor proteins. Tumor over-expression of one such protein, desmin, was quantified using immunofluorescence staining in a larger cohort. Dual staining for desmin and vimentin, or desmin and von Willebrand factor, was performed to determine the cell type of interest.

Results

Desmin expression was significantly increased between stage I and III tumors, (P < 0.0001), and stage II and III tumors, (P < 0.0001). Strong focal desmin expression was found in stroma directly adjacent to carcinomatous glands and microvessels. These cells showed co-localisation of desmin and vimentin in close association with cells expressing VWF, indicating they were pericytes. Significantly higher levels of desmin-positive pericytes were observed in late stage tumors, consistent with increased angiogenesis.

Conclusion

Pericyte coverage of vasculature is a marker of vessel maturation, hence desmin expression may have use as a marker for microvessel maturation. Clinical trials will be needed to determine its use in identifying tumors that will be less responsive to anti-angiogenic therapy.

【 授权许可】

   
2011 Arentz et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]O'Connell JB, Maggard MA, Ko CY: Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging. J Natl Cancer Inst 2004, 96:1420-1425.
• [2]Tsavellas G, Patel H, Allen-Mersh TG: Detection and clinical significance of occult tumour cells in colorectal cancer. Br J Surg 2001, 88:1307-1320.
• [3]Lloyd JM, McIver CM, Stephenson SA, Hewett PJ, Rieger N, Hardingham JE: Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res 2006, 12:417-423.
• [4]Hsu JY, Wakelee HA: Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor. BioDrugs 2009, 23:289-304.
• [5]De Wever O, Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 2003, 200:429-447.
• [6]Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF: Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999, 5:1041-1056.
• [7]Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999, 59:5002-5011.
• [8]Karagiannis GS, Pavlou MP, Diamandis EP: Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol Oncol 2010, 4:496-510.
• [9]Sugiyama Y, Farrow B, Murillo C, Li J, Watanabe H, Sugiyama K, Evers BM: Analysis of differential gene expression patterns in colon cancer and cancer stroma using microdissected tissues. Gastroenterology 2005, 128:480-486.
• [10]Lawrie LC, Curran S, McLeod HL, Fothergill JE, Murray GI: Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol 2001, 54:253-258.
• [11]Jin LT, Hwang SY, Yoo GS, Choi JK: A mass spectrometry compatible silver staining method for protein incorporating a new silver sensitizer in sodium dodecyl sulfate-polyacrylamide electrophoresis gels. Proteomics 2006, 6:2334-2337.
• [12]Ma Y, Peng J, Liu W, Zhang P, Huang L, Gao B, Shen T, Zhou Y, Chen H, Chu Z, et al.: Proteomics Identification of Desmin as a Potential Oncofetal Diagnostic and Prognostic Biomarker in Colorectal Cancer. Mol Cell Proteomics 2009, 8:1878-1890.
• [13]Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ, Caprioli RM: Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004, 4:793-811.
• [14]Alfonso P, Nunez A, Madoz-Gurpide J, Lombardia L, Sanchez L, Casal JI: Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics 2005, 5:2602-2611.
• [15]Álvarez-Chaver P, Rodríguez-Piñeiro AM, Rodríguez-Berrocal FJ, Martínez-Zorzano VS, Páez de la Cadena M: Identification of hydrophobic proteins as biomarker candidates for colorectal cancer. Int J Biochem Cell Biol 2007, 39:529-540.
• [16]De Wever O, Demetter P, Mareel M, Bracke M: Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008, 123:2229-2238.
• [17]Kunz-Schughart LA, Knuechel R: Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? Histol Histopathol 2002, 17:599-621.
• [18]Franco OE, Shaw AK, Strand DW, Hayward SW: Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 2010, 21:33-39.
• [19]Richman PI, Tilly R, Jass JR, Bodmer WF: Colonic pericrypt sheath cells: characterisation of cell type with new monoclonal antibody. J Clin Pathol 1987, 40:593-600.
• [20]Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR: Stromal Cells Promote Angiogenesis and Growth of Human Prostate Tumors in a Differential Reactive Stroma (DRS) Xenograft Model. Cancer Res 2002, 62:3298-3307.
• [21]Schmitt-Graff A, Desmouliere A, Gabbiani G: Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Virchows Arch 1994, 425:3-24.
• [22]Nehls V, Denzer K, Drenckhahn D: Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue Res 1992, 270:469-474.
• [23]Verhoeven D, Buyssens N: Desmin-positive stellate cells associated with angiogenesis in a tumour and non-tumour system. Virchows Arch B Cell Pathol Incl Mol Pathol 1988, 54:263-272.
• [24]Sims DE: The pericyte--A review. Tissue & Cell 1986, 18:153-174.
• [25]Kang N, Yaqoob U, Geng Z, Bloch K, Liu C, Gomez T, Billadeau D, Shah V: Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growth. Am J Pathol 2010, 177:1888-1900.
• [26]Brey EM, McIntire LV, Johnston CM, Reece GP, Patrick CW Jr: Three-dimensional, quantitative analysis of desmin and smooth muscle alpha actin expression during angiogenesis. Ann Biomed Eng 2004, 32:1100-1107.
• [27]Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G: PDGFR[beta]+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005, 7:870-879.
• [28]Armulik A, Abramsson A, Betsholtz C: Endothelial/pericyte interactions. Circ Res 2005, 97:512-523.
• [29]Raza A, Franklin MJ, Dudek AZ: Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 2010, 85:593-598.
• [30]Gerhardt H, Betsholtz C: Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003, 314:15-23.
• [31]Middleton J, Americh L, Gayon R, Julien D, Mansat M, Mansat P, Anract P, Cantagrel A, Cattan P, Reimund JM, et al.: A comparative study of endothelial cell markers expressed in chronically inflamed human tissues: MECA-79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146. J Pathol 2005, 206:260-268.
• [32]Schmid SA, Dietrich A, Schulte S, Gaumann A, Kunz-Schughart LA: Fibroblastic reaction and vascular maturation in human colon cancers. Int J Radiation Biol 2009, 85:1013-1025.
• [33]Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159-165.
• [34]Abramsson A, Berlin O, Papayan H, Paulin D, Shani M, Betsholtz C: Analysis of mural cell recruitment to tumor vessels. Circulation 2002, 105:112-117.
• [35]Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM: Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 2003, 162:183-193.
• [36]Jain RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
• [37]Pohl A, Zhang W, Ning Y, Manegold PC, Lurje G, Lenz H-J: Targeting metastatic colorectal cancer in 2008: a long way from 5-FU. (Special Issue on Targeted Therapy)(fluorouracil). Oncology 2008, 22:456-462.
• [38]Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C: Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 2007, 121:2606-2614.
• [39]Reinmuth N, Liu W, Jung YD, Ahmad SA, Shaheen RM, Fan F, Bucana CD, McMahon G, Gallick GE, Ellis LM: Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. Faseb J 2001, 15:1239-1241.
• [40]Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergün S, Schadendorf D: Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010, 207:491-503.